American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
SE
Semnur Pharmaceuticals, Inc.
$5.00
+1.01%
OTC: SMNR · 15-min delayed
$50.0MRevenue · FY2024
-$160.4MNet income
SMNROTC
About Semnur Pharmaceuticals, Inc.
SEMNUR PHARMS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2024
- $50.0M
- Net income
- -$160.4M
- Total assets
- $1.3M
Source: SEC EDGAR · updated Jun 8, 2026
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Reported a net loss of $160.4M in FY2024.
- Trading 78% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Semnur Pharmaceuticals, Inc..
Write a review
Newsroom
News about Semnur Pharmaceuticals, Inc.
Scilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in Bitcoin
News & sentiment via Polygon.io
Explore
Browse all →
